HOME >> BIOLOGY >> NEWS
New drug enfuvirtide shows promise against drug resistant HIV infection

CHAPEL HILL -- The new drug enfuvirtide, a member of a new class of medications designed to combat HIV -- the virus that causes AIDS -- shows strong promise in treating drug-resistant cases of the life-threatening infection, a study conducted with patients in North and South America concludes.

A report on the research appears in the May 29 issue of the New England Journal of Medicine.

"This is one of the most important studies performed to date in HIV-infected patients who have already received highly active antiretroviral therapy (HAART) and a landmark study for the field of HIV," said Dr. Joseph Eron of the University of North Carolina at Chapel Hill and a report author.

"The clinical work clearly demonstrates that a completely new class of anti-HIV medication, developed by a local company, Trimeris, is highly effective in a very large randomized study," said Eron, associate professor of medicine at the UNC School of Medicine.

"Enfuvirtide, or T-20, works by blocking HIV entry into CD4 + lymphocytes or T-cells and will benefit patients who already have HIV that is resistant to current therapy."

CD4+ lymphocytes, also known as T-cells, are a key part of the body's immune system for fighting off disease-causing viruses, bacteria and various other organisms, he said. HIV is so deadly because it kills those defenders and leaves patients vulnerable to a wide variety of debilitating illnesses.

Fuzeon is enfuvirtide's trade name.

Another report of a second study with similar results carried out in Europe and Australia also appears in the May 29 issue of the journal. Eron and Dr. J. Michael Kilby of the University of Alabama at Birmingham have a third article in the journal describing T-20 and other drugs now in development in the new class of HIV medications called entry inhibitors.

Dr. Jacob P. Lalezari of Quest Clinical Research, Mount Zion Hospital and the University of California at San Francisco led
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
28-May-2003


Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... 2015 - New Massive Open ... prepare for the United States Medical Licensing Examination ... technical and medical information products and services, announced today ... Online Course) designed to help medical students prepare for ... the first and most daunting of the three exams ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)... OncoTAb, Inc., a University of ... that Pinku Mukherjee, Ph.D. has received the O. ... highest faculty honor. Mukherjee received the award, which recognizes ... innovative research and development of cancer diagnostics and treatments. ... moment in my scientific career,” said Mukherjee, OncoTAb Co-founder ...
Breaking Biology Technology:Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
Cached News: